Simulations Plus, Inc. (NASDAQ:SLP) faces challenges in the biopharma market, leading KeyBanc to downgrade its stock rating to “Sector Weight” due to ongoing customer demand issues. Despite this, in Q3 2025, the company saw a 10% increase in revenue, driven by strong software and services performance. A strategic reorganization aims for revenue between $76 million – $80 million for FY 2025.

Simulations Plus, Inc. (NASDAQ:SLP) develops software for pharmaceutical research and education, offering consulting and contract research services to the industry. While SLP shows potential as an investment, other AI stocks may offer greater upside potential with less downside risk. For investors seeking undervalued AI stocks, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: KeyBanc Downgrades Simulations Plus (SLP) Stock to Sector Weight